Table 1.
Baseline clinical and pathological characteristics by time to surgery after diagnosis, The Ruijin cohort.
| Characteristics | Total N = 3144 (%) |
≤ 1week N = 2859 (%) |
1–2 weeks N = 176 (%) |
> 2 weeks N = 109 (%) |
P value |
|---|---|---|---|---|---|
| Age (y/o) | |||||
| < 40 | 277 (8.8) | 236 (8.3) | 28 (15.9) | 13 (11.9) | < 0.001 |
| 40–49 | 719 (22.9) | 642 (22.5) | 53 (30.1) | 24 (22.0) | |
| 50–70 | 1765 (56.1) | 1647 (57.6) | 69 (39.2) | 49 (45.0) | |
| > 70 | 383 (12.2) | 334 (11.7) | 26 (14.8) | 23 (21.1) | |
| Menstrual status | |||||
| Pre/Peri- | 1132 (36.0) | 1002 (35.0) | 91 (51.7) | 39 (35.8) | < 0.001 |
| Post- | 1998 (63.6) | 1847 (64.7) | 84 (47.7) | 67 (61.5) | |
| NA | 14(0.4) | 10(0.3) | 1(0.6) | 3(2.8) | |
| Residence area | |||||
| Large metropolitan | 1813 (57.7) | 1650 (57.7) | 96 (54.5) | 67 (61.5) | 0.845 |
| Metropolitan | 114 (3.6) | 104 (3.6) | 6 (3.4) | 4 (3.7) | |
| Urban | 337 (10.7) | 313 (10.9) | 17 (9.7) | 7 (6.4) | |
| Rural | 787 (25.0) | 708 (24.8) | 51 (29.0) | 28 (25.7) | |
| NA | 93 (3.0) | 84 (2.9) | 6 (3.4) | 3 (2.8) | |
| CCI | |||||
| 0 | 1855 (59.0) | 1701 (59.5) | 111 (63.1) | 43 (39.4) | < 0.001 |
| 1–2 | 967 (30.8) | 878 (30.7) | 46 (26.1) | 43 (39.4) | |
| 3 + | 322 (10.2) | 280 (9.8) | 19 (10.8) | 23 (21.1) | |
| Education level | |||||
| Post-graduated | 49 (1.6) | 46 (1.6) | 3 (1.7) | 0 (0) | 0.227 |
| Degree | 788 (25.1) | 702 (24.6) | 52 (29.5) | 34 (31.2) | |
| High school | 964 (30.7) | 887 (31.0) | 48 (27.3) | 29 (26.6) | |
| Middle school | 1161 (36.9) | 1065 (37.3) | 60 (34.1) | 36 (33.0) | |
| NA | 182 (5.8) | 159 (5.6) | 13 (7.4) | 10 (9.2) | |
| BMI | |||||
| < 25 | 2228 (70.9) | 2027 (70.9) | 131 (74.4) | 70 (64.2) | 0.287 |
| 25–30 | 737 (23.4) | 673 (23.5) | 32 (18.2) | 32 (29.4) | |
| ≥ 30 | 114 (3.6) | 103 (3.6) | 8 (4.5) | 3 (2.8) | |
| NA | 65 (2.1) | 56 (2.0) | 5 (2.8) | 4 (3.7) | |
| Breast surgery | |||||
| BCS | 864 (27.5) | 793 (27.7) | 46 (26.1) | 25 (22.9) | 0.501 |
| Mastectomy | 2280 (72.5) | 2066 (72.3) | 130 (73.9) | 84 (77.1) | |
| Axillary surgery | |||||
| SLNB | 1727 (54.9) | 1572 (55.0) | 92 (52.3) | 63 (57.8) | 0.617 |
| ALND | 1405 (44.7) | 1279 (44.7) | 82 (46.6) | 44 (40.4) | |
| NA | 12(0.4) | 8(0.3) | 2(1.1) | 2(1.8) | |
| Histology type | |||||
| IDC | 2760 (87.8) | 2511 (87.8) | 156 (88.6) | 93 (85.3) | 0.690 |
| Non-IDC | 384 (12.2) | 348 (12.2) | 20 (11.4) | 16 (14.7) | |
| Tumor size | |||||
| ≤ 2.0 cm | 1623 (51.6) | 1490 (52.1) | 81 (46.0) | 52 (47.7) | 0.227 |
| > 2.0 cm | 1519 (48.3) | 1368 (47.8) | 94 (53.4) | 57 (52.3) | |
| NA | 2(0.1) | 1(0.1) | 1(0.6) | 0 | |
| ALN status | |||||
| Negative | 1947 (61.9) | 1773 (62.0) | 107 (60.8) | 67 (61.5) | 0.944 |
| Positive | 1197 (38.1) | 1086 (38.0) | 69 (39.2) | 42 (38.5) | |
| Tumor stage | |||||
| I | 1134 (36.1) | 1041 (36.4) | 59 (33.5) | 34 (31.2) | 0.238 |
| II | 1539 (49.0) | 1384 (48.4) | 91 (51.7) | 64 (58.7) | |
| III | 471 (15.0) | 434 (15.2) | 26 (14.8) | 11 (10.1) | |
| Histological grade | |||||
| I | 164 (5.2) | 142 (5.0) | 10 (5.7) | 12 (11.0) | 0.153 |
| II | 1549 (49.3) | 1413 (49.4) | 89 (50.6) | 47 (43.1) | |
| III | 1083 (34.4) | 990 (34.6) | 58 (33.0) | 35 (32.1) | |
| NA | 348 (11.1) | 314 (11.0) | 19 (10.8) | 15 (13.8) | |
| LVI | |||||
| Negative | 2831 (90.0) | 2577 (90.1) | 154 (87.5) | 100 (91.7) | 0.438 |
| Positive | 313 (10.0) | 282 (9.9) | 22 (12.5) | 9(8.3) | |
| ER | |||||
| Negative | 887 (28.2) | 800 (28.0) | 55 (31.2) | 32 (29.4) | 0.623 |
| Positive | 2257 (71.8) | 2059 (72.0) | 121 (68.8) | 77 (70.6) | |
| PR | |||||
| Negative | 1302 (41.4) | 1175 (41.1) | 81 (46.0) | 46 (42.2) | 0.430 |
| Positive | 1842 (58.6) | 1684 (58.9) | 95 (54.0) | 63 (57.8) | |
| HER2 | |||||
| Negative | 2332 (74.2) | 2112 (73.9) | 130 (73.9) | 90 (82.6) | 0.125 |
| Positive | 812 (25.8) | 747 (26.1) | 46 (26.1) | 19 (17.4) | |
| Ki67 | |||||
| < 14% | 953 (30.3) | 869 (30.4) | 54 (30.7) | 30 (27.5) | 0.810 |
| ≥ 14% | 2191 (69.7) | 1990 (69.6) | 122 (69.3) | 79 (72.5) | |
| Molecular subtype | |||||
| HR + /HER2 − | 1877 (59.7) | 1703 (59.6) | 105 (59.7) | 69 (63.3) | 0.275 |
| HER2 + | 812 (25.8) | 747 (26.1) | 46 (26.1) | 19 (17.4) | |
| TNBC | 455 (14.5) | 409 (14.3) | 25 (14.2) | 21 (19.3) | |